The Omicron-adapted COVID-19 vaccine booster developed by Pfizer Inc and BioNTech SE sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab's real-world effectiveness.
sharply reduced hospitalizations among older patients, Israeli researchers said on Monday, in some of the first evidence of the jab's real-world effectiveness.
It found an 81% reduction in hospitalizations among people aged 65 and older who had received the booster against those who had previously received at least two COVID vaccinations, but not the Omicron-adapted shot. "Hospitalization due to Covid-19 occurred in 6 bivalent recipients and 297 participants who did not" receive it, the study said. "Death due to Covid-19 occurred in 1 bivalent recipient and 73 participants who did not."
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Omicron XBB.1.5: What Do We Know So Far?The latest mutation of Omicron could increase COVID-19 cases in the UK but is unlikely to make us sicker, experts said.
Les mer »
Omicron variant XBB.1.5 is the most contagious yetPreliminary research on parent strain XBB has shown that the virus attaches more tightly to human cells than other Omicron variants, such as BA.2.75 and BA.2
Les mer »
Most people who ended up with long COVID started with a mild case, new study showsThe researchers found 'a staggering' 90% of people living with long COVID only had a mild illness to start \u2014\u00a0but people who were hospitalized were more likely to develop the lasting symptoms.
Les mer »